IRFZX
Price
$8.93
Change
-$0.02 (-0.22%)
Updated
Jun 18 closing price
Net Assets
236.89M
VGRNX
Price
$90.58
Change
-$0.21 (-0.23%)
Updated
Jun 18 closing price
Net Assets
3.8B
Interact to see
Advertisement

IRFZX vs VGRNX

IRFZX vs VGRNX Comparison Chart in %
View a ticker or compare two or three
VS
IRFZX vs. VGRNX commentary
Jun 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IRFZX is a Hold and VGRNX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VGRNX has more cash in the bank: 3.8B vs. IRFZX (237M). IRFZX pays higher dividends than VGRNX: IRFZX (6.10) vs VGRNX (4.68). IRFZX was incepted earlier than VGRNX: IRFZX (11 years) vs VGRNX (15 years). IRFZX (1.19) is less costly to investors than VGRNX (0.11). IRFZX is a more actively managed with annual turnover of: 67.00 vs. VGRNX (10.00). IRFZX has a lower initial minimum investment than VGRNX: IRFZX (0) vs VGRNX (5000000). VGRNX annual gain was more profitable for investors over the last year : 3.82 vs. IRFZX (3.36). VGRNX return over 5 years is better than : -9.16 vs. IRFZX (-15.81).
IRFZXVGRNXIRFZX / VGRNX
Total Expense Ratio1.000.11909%
Annual Report Gross Expense Ratio1.190.111,082%
Fund Existence11 years15 years-
Gain YTD-2.083-2.26692%
Front LoadN/AN/A-
Min. Initial Investment05000000-
Min. Initial Investment IRAN/AN/A-
Net Assets237M3.8B6%
Annual Yield % from dividends6.104.68130%
Returns for 1 year3.363.8288%
Returns for 3 years4.1411.8935%
Returns for 5 years-15.81-9.16173%
Returns for 10 years27.0416.52164%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FELCX158.828.30
+5.51%
Fidelity Advisor Semiconductors C
FIICX22.070.30
+1.38%
Fidelity Advisor Mid Cap II C
DVRUX18.820.16
+0.86%
UBS US Dividend Ruler P
WPLCX19.980.05
+0.25%
WP Large Cap Income Plus Institutional
EIHSX12.82-0.11
-0.85%
Eaton Vance Worldwide Health Sci I